精神分裂症治疗相关靶点及药物研究进展.pdfVIP

Pharmacy Information 药物资讯, 2016, 5(2), 19-24 Published Online May 2016 in Hans. /journal/pi /10.12677/pi.2016.52004 Receptors and Related Drug Development for Schizophrenia: Research Advances Xiaofeng Jia, Ling He* China Pharmaceutical University, Nanjing Jiangsu nd th th Received: Apr. 2 , 2016; accepted: Apr. 26 , 2016; published: Apr. 29 , 2016 Copyright © 2016 by authors and Hans Publishers Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). /licenses/by/4.0/ Abstract Schizophrenia is a chronic disabling mental disorder. Because of its severity, chronicity, early age of onset, and prevalence, schizophrenia is the source of enormous human and economic costs. At present, schizophrenia is treated with typical and atypical antipsychotics. However, typical anti- psychotics are effective only in treating positive symptoms, and they may result in extrapyramidal side-effects. Although atypical antipsychotics have a certain improvement in negative symptoms and cognitive impairment and do not produce the extrapyramidal side-effects, there are other side effects. Therefore, we need more effective and safer antipsychotics. Recent studies found that those receptors associated with schizophrenia, such as dopamine receptor, 5-hydroxytryptamine receptor, glutamate receptor, cannabinoid receptor, sigma receptor and so on. This review sum- marizes the receptors and relevant drug development associated with Schizophrenia in recent years. Keywords Schizophrenia, Treatment Drugs, Receptors 精神分裂症治疗相关靶点及药物研究进展 贾晓凤，何 玲* 中国药科大学，江苏 南京 *通讯作者。 文章引用: 贾晓凤, 何玲. 精神分裂症治疗相关靶点及药物研究进展[J].